Nodal marginal zone lymphoma

Leukemia and Lymphoma

Volumn 55, Issue 6, 2014, Pages 1240-1250

  Angelopoulou, Maria K ^a   Kalpadakis, Christina ^c   Pangalis, Gerassimos A ^d   Kyrtsonis, Marie Christine ^b   Vassilakopoulos, Theodoros P ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

^d ATHENS MEDICAL CENTER   (Greece)

Author keywords

Lymphoma; Marginal zone; NMZL

Indexed keywords

RITUXIMAB;

CANCER CLASSIFICATION; CANCER STAGING; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; GENETICS; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; MARGINAL ZONE LYMPHOMA; NODAL MARGINAL ZONE LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPLENIC MARGINAL ZONE LYMPHOMA; SURVIVAL RATE; CANCER GRADING; COMPLICATION; GENETIC PREDISPOSITION; HEPACIVIRUS; HEPATITIS C; LYMPH NODE; LYMPHOMA, B-CELL; MUTATION; PATHOLOGY;

DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHOMA, B-CELL; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS;

EID: 84901329456     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.840888     Document Type: Review

References (66)

1. Campo E, Pileri SA, Jaffe E S, et al. Nodal marginal zone lymphoma (NMZL). In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp 218-219
2. Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. CD5-monoclonal B-cell lymphoproliferation (MBL): Clinical characteristics and outcome. Haematologica 2012; 97(Suppl. 1): Abstract 215
3. Sheibani K, Sohn CS, Burke JS, et al. Monocytoid B-cell lymphoma. Am J Pathol 1986; 124: 310-318
4. Cousar JB, McGinn DL, Glick AD, et al. Report of an unusual lymphoma arising from parafollicular B-lymphocytes (PBLS) or so-called monocytoid lymphocytes. Am J Clin Pathol 1987; 87: 121-128
5. Piris M A, Rivas C, Morente M, et al. Monocytoid B-cell lymphoma, a tumour related to the marginal zone. Histopathology 1988; 12 : 383-392
6. Harris NL, Jaffe ES, Stein H, et al. Arevised European-American classifi cation of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392
7. Isaacson PG, Nathwani BN, Piris MA, et al. Nodal marginal zone lymphoma. In: Jaffe ES, Harris NL, Stein H, et al., editors. Pathology and genetics: Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. p 161
8. Olszewski AJ, Castillo JJ. Survival of patients wiThmarginal zone lymphoma: Analysis of the surveillance, epidemiology, and end results database. Cancer 2013; 119: 629-638
9. Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients wiThB-cell non-Hodgkin lymphoma. Ann Intern Med 1997; 127: 423-428. (Pubitemid 27400904
10. Arcaini L, Burcheri S, Rossi A, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 2007; 18: 346-350. (Pubitemid 46323104
11. Kojima M, Tsukamoto N, Miyazawa Y, et al. Nodal marginal zone B-cell lymphoma associated wiThSjögren's syndrome: A report of three cases. Leuk Lymphoma 2007; 48: 1222-1224. (Pubitemid 47009215
12. Nathwani BBN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosaassociated lymphoid tissue types. JClin Oncol 1999; 17: 2486-2492. (Pubitemid 29368249
13. Berger F, Felman P, Thieblemont C, et al. Non-malt marginal zone B-cell lymphomas: A description of clinical presentation and outcome in 124 patients. Blood 2000; 95: 1950-1956
14. Camacho FI, Algara P, Mollejo M, et al. Nodal marginal zone lymphoma: A heterogeneous tumor: A comprehensive analysis of a series of 27 cases. Am J Surg Pathol 2003; 27: 762-771. (Pubitemid 36617512
15. Traverse-Glehen A, Felman P, Callet-Bauchu E, et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology 2006; 48: 162-173
16. Oh SY, Ryoo B-Y, Kim WS, et al. Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol 2006; 85: 781-786
17. Kojima M, Inagaki H, Motoori T, et al. Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: Study of 65 cases. Cancer Sci 2007; 98: 44-49. (Pubitemid 44803919
18. Arcaini L, Paulli M, Burcheri S, et al. Primary nodal marginal zone B-cell lymphoma: Clinical features and prognostic assessment of a rare disease. Br J Haematol 2007; 136: 301-304. (Pubitemid 46020759
19. Heilgeist A, McClanahan F, Ho AD, et al. Prognostic value of the follicular lymphoma international prognostic index score in marginal zone lymphoma: An analysis of clinical presentation and outcome in 144 patients. Cancer 2013; 119: 99-106
20. Taddesse-HeaThL, Pittaluga S, Sorbara L, et al. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol 2003; 27: 522-531. (Pubitemid 36368552
21. Nathwani BN, Mohrmann RL, Brynes RK, et al. Monocytoid B-cell lymphomas: An assessment of diagnostic criteria and a perspective on histogenesis. Hum Pathol 1992; 23: 1061-1071
22. Petit B, Chaury MP, Le Clorennec C, et al. Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: Absence of boThIRF4 and Ki67 expression identifi es a better prognosis subgroup. Haematologica 2005; 90: 200-206. (Pubitemid 40293281
23. Molina T J, Lin P, Swerdlow S H, Cook J R. M arginal zone lymphomas wiThplasmacytic diff erentiation and related disorders. Am J Clin Pathol 2011; 136: 211-225
24. Van Den Brand M, van Krieken JHJM. Recognizing nodal marginal zone lymphoma: Recent advances and pitfalls. Asystematic review. Haematologica 2013; 98: 1003-1013
25. Aamot HV, Micci F, Holte H, et al. G-banding and molecular cytogenetic analyses of marginal zone lymphoma. Br J Haematol 2005; 130: 890-901. (Pubitemid 43899730
26. Callet-Bauchu E, Baseggio L, Felman P, et al. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-malt marginal zone B-cell lymphomas among mature B-cell entities: A description of 103 cases. Leukemia 2005; 19: 1818-1823. (Pubitemid 41486161
27. Braggio E, Dogan A, Keats JJ, et al. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identifi ed common and disease-specifi c abnormalities. Mod Pathol 2012; 25: 651-660
28. Ferreira BI, Garcí a JF, Suela J, et al. Comparative genome profi ling across subtypes of low-grade B-cell lymphoma identifi es type-specifi c and common aberrations that target genes wiTha role in B-cell neoplasia. Haematologica 2008; 93: 670-679
29. Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of diff erent sites share similar cytogenetic and morphologic features. Blood 1996; 87: 299-307. (Pubitemid 26011844
30. Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profi ling of marginal zone lymphomas identifi es subtypespecifi c lesions wiThan impact on the clinical outcome. Blood 2011; 117: 1595-1604
31. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specifi city of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol 2000; 156 : 1183-1188. (Pubitemid 30659996
32. Baens M, Finalet Ferreiro J, Tousseyn T, et al. t(x;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34. Haematologica 2012; 97: 184-188
33. Stary S, Vinatzer U, Mullauer L, et al. t (11;14)(q23;q32) involving IGH and DDX6 in nodal marginal zone lymphoma. Genes Chromosomes Cancer 2013; 43: 33-43
34. Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma wiThrituximab monotherapy: Progress report and comparison wiThsplenectomy. Oncologist 2013; 18: 190-197
35. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: A study of 766 patients. JNucl Med 2010; 51: 25-30
36. Novak U, Basso K, Pasqualucci L, et al. Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells. Br J Haematol 2011; 155: 362-365
37. Traverse-Glehen A, Davi F, Simon EB, et al. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica 2005; 90: 470-478. (Pubitemid 40592889
38. Conconi A, Bertoni F, Pedrinis E, et al. Nodal marginal zone B-cell lymphomas may arise from diff erent subsets of marginal zone B lymphocytes. Blood 2001; 98: 781-786
39. Marasca R, Vaccari P, Luppi M, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 2001; 159: 253-261. (Pubitemid 33704210
40. Tierens A, Delabie J, Michiels L, et al. Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion. Blood 1999; 93: 226-234. (Pubitemid 29019407
41. Traverse-Glehen A, Verney A, Baseggio L, et al. Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin. Leukemia 2007; 21: 1821-1824. (Pubitemid 47086773
42. Arribas AJ, Campos-Martí n Y, Gó m ez-Abad C, et al. Nodal marginal zone lymphoma: Gene expression and miRNA profi ling identify diagnostic markers and potential therapeutic targets. Blood 2012; 119: E9-e21
43. Baldini L, Brugiatelli M, Luminari S, et al. Treatment of indolent B-cell nonfollicular lymphomas: Fi nal results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. JClin Oncol 2003; 21: 1459-1465. (Pubitemid 46594096
44. Orciuolo E, Buda G, Sordi E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 2010; 34: 184-189
45. Kuper-Hommel M JJ, Van De Schans S AM, Vreugdenhil G, et al. Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: Declining incidence and inferior outcome for gastrointestinal sites. Leuk Lymphoma 2013 ; 54: 1891-1897
46. Hochster HS, Oken MM, Winter JN, et al. Phase I study of fl udarabine plus cyclophosphamide in patients wiThpreviously untreated low-grade lymphoma: Results and and long-Term follow-up-A report from the Eastern Cooperative Oncology Group. JClin Oncol 2000; 18: 987-994. (Pubitemid 30123774
47. Ferrario A, Merli F, Luminari S, et al. Phase II fl udarabine and cyclophosphamide for the treatment of indolent B cell nonfollicular lymphomas: Fi nal results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Ann Hematol 2011; 90 : 323-330
48. Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a fi rst-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol 2012; 91: 543-551
49. Brown J R, Friedberg J W, Feng Y, et al. Aphase 2 study of concurrent fl udarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 2009; 145: 741-748
50. Ferrario A, Pulsoni A, Olivero B, et al. Fludarabine, cyclophosphamide, and rituximab in patients wiThadvanced, untreated, indolent B-cell nonfollicular lymphomas: Phase 2 study of the Italian Lymphoma Foundation. Cancer 2012; 118: 3954-3961
51. Rummel M J, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as fi rst-line treatment for patients wiThindolent and mantle-cell lymphomas: An openlabel, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210
52. Rummel MJ, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fl udarabine plus rituximab in patients wiThrelapsed follicular, indolent and mantle cell lymphomas-fi nal results of the randomized phase III study NHL 2-2003 on behalf of the STIL. Blood. 2010; 116(Suppl. 1): Abstract 856
53. Oh SY, Kim WS, Lee DH, et al. Phase II study of gemcitabine for treatment of patients wiThadvanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Invest New Drugs 2010; 28: 171-177
54. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. JClin Oncol 2003; 21: 1263-1270. (Pubitemid 46606402
55. Brown J R, Gaudet G, Friedberg J W, et al. Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma 2004; 45: 315-320. (Pubitemid 38181434
56. Li L, Bierman P, Vose J, et al. High-Dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2011; 11: 253-256
57. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. JClin Oncol 2009; 27: 3346-3353
58. Goy A, Leach J, Ehmann WC, et al. Inotuzumab ozogamicin (CMC-544) in patients wiThindolent B-cell NHL that is refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy: Preliminary safety and Efficacy from a phase 2 trial. Blood 2010 ; 116(Suppl. 1): Abstract 430
59. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience wiThthe novel proteasome inhibitor bortezomib in patients wiThindolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-684. (Pubitemid 46237441
60. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients wiThrelapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117: 2807-2812
61. Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. JClin Oncol 2011; 29: 1198-1203
62. Witzig T E, Wiernik P H, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin' s lymphoma. JClin Oncol 2009; 27: 5404-5409
63. Fowler NH, McLaughlin P, Hagemeister FB, et al. Complete response rates wiThlenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin' s lymphoma. JClin Oncol 2010; 28 :(15S Suppl.): Abstract 8036
64. Turner N C, Dusheiko G, Jones A. Hepatitis C and B-cell lymphoma. Ann Oncol 2003; 14: 1341-1345
65. Chan CH, Hadlock KG, Foung SKH, et al. VH1-69 gene is preferentially used by hepatitis C virus-Associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 2001; 97: 1023-1026. (Pubitemid 32154288
66. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: A multicenter Italian experience. JClin Oncol 2005; 23 : 468-473. (Pubitemid 46224223